NeuroSense Therapeutics

Drug for ALS

Health Tech & Life Sciences
Public on NASDAQ on Dec, 2021

Company Overview

Snapshot

Founded in February 2017 by Alon Ben-Noon, NeuroSense Therapeutics operates with 11–50 employees. The company has raised $24.2M across 7 funding rounds and went public on NASDAQ in December 2021.

Business overview

NeuroSense Therapeutics is a drug development company focused on creating treatments for patients suffering from amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its core product, PrimeC, is a unique formulation combining two FDA-approved compounds. The company serves the pharmaceutical and life sciences markets, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for its lead drug candidate, PrimeC, in ALS. This significant regulatory advancement signals a critical step forward in the company's clinical development pathway and validates the potential of PrimeC, indicating a strong forward trajectory for investors in the neurodegenerative disease treatment market.

Company Intelligence Q&A

What is NeuroSense Therapeutics' primary drug candidate?
NeuroSense Therapeutics' primary drug candidate is PrimeC, a unique formulation combining two FDA-approved compounds for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
When did NeuroSense Therapeutics go public?
NeuroSense Therapeutics went public on NASDAQ in December 2021.
What was a recent regulatory milestone for NeuroSense Therapeutics?
In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for PrimeC in ALS.
What recent patent was granted to NeuroSense Therapeutics?
In September 2024, NeuroSense Therapeutics was granted a key U.S. patent for its novel PrimeC formulation, which is its lead asset for ALS and Alzheimer's.
What is NeuroSense Therapeutics' plan for commercialization in Canada?
In October 2024, NeuroSense Therapeutics announced plans to file for early commercialization of its ALS treatment in Canada, with further updates provided in October 2024.

External links